Natalie Finn, Author at BioTuesdays

Developments

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

Avenue Therapeutics’ (NASDAQ:ATXI) BAER-101, its potentially best-in-class selective GABA-A alpha2,3 positive allosteric modulator significantly suppressed seizures in a translational animal model of absence epilepsy...

August 1, 2023

Markets

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Leerink slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $4 from $15, but maintained its “outperform” rating after the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary...

July 27, 2023

Developments

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and...

July 27, 2023

Developments

Carmell to merge with Axoloti Biologix

Carmell Therapeutics (NASDAQ:CTCX) signed a definitive agreement and plan of merger with Axoloti Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and...

July 27, 2023

Developments

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

Humacyte (NASDAQ:HUMA) completed enrollment of its Phase 2/3 vascular trauma trial that is expected to support a BLA filing for Humacyte’s human acellular vessel (HAV) in vascular trauma repair planned for the fourth...

July 26, 2023

Developments

Symetryx ups offer for Check-Cap to $4.60 a share

Closely-held Symetryx increased its non-binding proposal to acquire Check-Cap (NASDAQ:CHEK) to $4.60 a share from $4.35 when it announced its offer on July 18. At last report, Check-Cap had 5.8 million shares...

July 25, 2023

Developments

Enzo sells clinical laboratory to Labcorp for $113.25-million

Enzo Biochem (NYSE:ENZ) closed a transaction to sell certain assets of Enzo’s clinical laboratory division (Enzo Clinical Labs) to Laboratory Corp. of America Holdings (NYSE:LH) for $113.25-million. In accordance with...

July 25, 2023

Developments

Axxess acquires Complia Health

Axxess, a home healthcare technology provider, acquired Complia Health in move that adds more clients, more talent and even greater engagement with leading care providers among the Axxess family. Complia’s roster of...

July 24, 2023

Developments

Eliem Therapeutics to explore strategic alternatives

Eliem Therapeutics (NASDAQ:ELYM) completed a review of its business, including the status of its programs, resources, and capabilities, and has decided to halt further development of its Kv7 program and to conduct a...

July 20, 2023

Developments

Athira presents biomarker data in Alzheimer’s

Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...

July 17, 2023

Author - Natalie Finn

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

Carmell to merge with Axoloti Biologix

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

Symetryx ups offer for Check-Cap to $4.60 a share

Enzo sells clinical laboratory to Labcorp for $113.25-million

Axxess acquires Complia Health

Eliem Therapeutics to explore strategic alternatives

Athira presents biomarker data in Alzheimer’s

General

More